linjc16/ctgov huggingface dataset:
Band Adhesions in Relation to Previous Abdominal Surgery

Study Overview
=================
Brief Summary
-----------------
This study investigates the prevalence of previous abdominal surgery in a cohort of patients operated for bowel obstruction and analyzes the causes of obstruction discovered at surgery.

Detailed Description
-----------------
Postoperative intra-abdominal adhesions are a common cause of small bowel obstruction. The extent of adhesions has been assigned to the magnitude of previous surgery. In a county hospital, with a catchment population of 120 000 inhabitants, records of operations performed for bowel obstruction over a period of 70 months were retrieved. Codes for bowel obstruction according to an International Classification of Diseases (ICD-10) will include: Intestinal adhesion with obstruction, Other and unspecified intestinal obstruction, Intestinal obstruction and Peritoneal adhesions. Amount of adhesions will be calculated in relation to previous surgery.

Official Title
-----------------
Band Adhesions in Relation to Previous Abdominal Surgery - a Retrospective Analysis of Risk Factors

Conditions
-----------------
Surgical Adhesions, Intestinal Obstruction, Surgery Induced Tissue Adhesions

Intervention / Treatment
-----------------
* Procedure: Intestinal obstruction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects operated for bowel obstruction -from January 1st 2006 to October 31st 2011 Surgical codes for bowel obstruction: Intestinal adhesion with obstruction Other and unspecified intestinal obstruction Intestinal obstruction Unspecified and Peritoneal adhesions Surgical procedures identified for bowel obstruction: Division of band adhesion Adhesiolysis Other separation of adhesion during bowel obstruction Laparotomy and reposition or detorsion of intestine. Exclusion Criterias: -Extra-peritoneal surgery such as inguinal or ventral hernia repair was excluded.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Intestinal obstruction|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cause of bowel obstruction | Bowel obstruction; caused by adhesions, malignant disease, inflammation or other causes | 70 months |
Effect of Kettlebell Training on Musculoskeletal and Cardiovascular Health

Study Overview
=================
Brief Summary
-----------------
Neck/shoulder and back pain is quite common among employees in sedentary occupations. Furthermore, many have a low level of fitness. Strength training with dumbbells has been shown to alleviate neck/shoulder pain, but many people prefer to also have alternative training options. Empirically, kettlebell training works the neck/shoulder/back while at the same time training the cardiovascular system. This type of training has not previously been tested in a randomized controlled trial. The aim of this study is to test the effect of kettlebell training on musculoskeletal pain, fitness, and muscle strength.

Official Title
-----------------
Effect of Kettlebell Training on Musculoskeletal and Cardiovascular Health

Conditions
-----------------
Musculoskeletal Disorders

Intervention / Treatment
-----------------
* Behavioral: Ketllebell training
* Behavioral: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: employed office workers Exclusion Criteria: trauma life threatening diseases pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ketllebell group<br>Basic ketllebell training 3 x 20 min a week for 8 weeks | Behavioral: Ketllebell training<br>* Kettlebell training 3 x 20 min a week for 8 weeks<br>|
| Sham Comparator: Control group<br>Control group. Receives a health examination before and after the intervention period, and are advised to stay active. | Behavioral: Control<br>* Receives a health examination before and after the intervention period, and are advised to stay active.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain in the neck/shoulder and back |  | before and after the 8-week intervention | 
| Muscle strength |  | before and after the 8-week intervention | 
| Fitness (VO2-max) |  | before and after the 8-week intervention |
Study of the Corelation Between Circulating Nuclearsome and SIRS Happened After Congential Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
In this study，the investigators want to determine the corelation between circulating nuclearsome and the development of SIRS occured after congenital cardiac surgery, including the serverity of organ damage and inflamation.

Detailed Description
-----------------
Blood was collected from study participants at 6 time points; 1) post-anesthesia induction, 2) post-op hour 0, 3) post-op hour 4, 4) post-op hour 24, 5) post-op hour 48, and 6) post-op hour 72. At each of the 6 time points blood was analyzed for levels of the following:histone,blood routine test , c-reaction protein, procalcitonin, N-terminal pro-brain natriuretic,the hepatorenal function，cardiac function and pulmonary function

Official Title
-----------------
Corelation Between Circulating Nuclearsome and SIRS Happened After Congential Cardiac Surgery

Conditions
-----------------
Congential Cardiac Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children with congenial heart disease Exclusion Criteria: Less than 2.5kg Prematurity less than 37 weeks estimated gestational age Renal failure as described by the pediatric RIFLE criteria

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| category of RACHS-2 for cardiac surgery<br>ASD & VSD repair; VSD repair; Tetralogy repair; Tetralogy repair | |
| category of RACHS-3 for cardiac surgery<br>DORV repair with or without RV obstruction; AVSD (complete or transitional) repair with or without valve replacement; Coarctation & VSD repair | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the perioperation change of histone level |  | preoperation to 72 hours after congential cardiac surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the perioperation change of c-reaction protein level |  | preoperation to 72 hours after congential cardiac surgery | 
| the perioperation change of cardiac function |  | preoperation to 72 hours after congential cardiac surgery | 
| the perioperation change of blood routine test |  | preoperation to 72 hours after congential cardiac surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
congential cardiac surgery, nuclearsome, systemic inflammation response syndrome
The Optimization of Blood Pressure and Fluid Status Control With Eight-Polar Bioelectrical Impedance Analysis

Study Overview
=================
Brief Summary
-----------------
Peritoneal dialysis (PD) is a widely used modality of renal replacement therapy. Due to its continuous nature of therapy, better control of fluid status and preservation of residual renal function were presumed by most nephrologists. However, recent evidences showed that it might not be the case. The severity of fluid overloading and the need for anti-hypertensive agents to control blood pressure seems to be more severe for PD patients. Therefore, more aggressive strategy to control dry weight is mandatory in PD patients. However, over reduction of dry weight might affect residual renal function (RRF) and, probably, the survival of PD patients. A balance between reduction of dry weight and preservation of RRF is crucial for the care of PD patients. Currently, only clinical measures like cardiothoracic ratio on chest X-ray and absence of pedal edema were used to evaluate PD patient's dry weight. There is no objective method to determine dry weight accurately. In this prospective and randomized study, the investigators will use multi-frequency bio-impedance (MF-BIA) to detect intracellular and extracellular water (ECW) content of patients.

Official Title
-----------------
The Optimization of Blood Pressure and Fluid Status Control With Eight-Polar Bioelectrical Impedance Analysis

Conditions
-----------------
Hypertension, Fluid Overload, Heart Diseases

Intervention / Treatment
-----------------
* Device: Bioelectrical impedance-guide dry weight reduction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18 to 80 Exclusion Criteria: type I DM Severe heart failure unstable angina

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Monthly BIA<br>monthly BIA to monitor fluid status | Device: Bioelectrical impedance-guide dry weight reduction<br>* for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| systolic blood pressure |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bioimpedance, ultrafiltration, blood pressure, pulse pressure
Trial of VLTS-589 in Subjects With Intermittent Claudication

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and tolerability of VLTS-589 compared with placebo, administered bilaterally to the lower extremities, in subjects with intermittent claudication and to determine the effect of VLTS-589 in peak walking time (PWT) for subjects receiving VLTS-589 compared with subjects receiving placebo.

Official Title
-----------------
A Phase II Multicenter, Double-Blind, Placebo-Controlled, Trial of VLTS-589 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease

Conditions
-----------------
Intermittent Claudication, Peripheral Vascular Disease

Intervention / Treatment
-----------------
* Genetic: Plasmid based Gene Transfer product-VLTS-589


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Men or women between 40 and 80 years of age, Must give informed consent, Current medical history of peripheral arterial disease, which includes the following symptoms: leg pain, leg discomfort or leg weakness Exclusion criteria: Ulcers or gangrene, History of cancer (except skin cancer) within the past 5 years, Participation in another clinical trial within 30 days of enrollment in this trial, Unwillingness or inability to comply with all study requirements

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: Plasmid based Gene Transfer product-VLTS-589|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effect of an approved medication on the symptoms of seasonal allergic rhinitis (a seasonal variety of inflammation of the mucous membrane of the nose) in patients who are experiencing symptoms of seasonal allergic rhinitis and asthma.

Detailed Description
-----------------
The duration of treatment is 2 weeks.

Official Title
-----------------
A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients With Seasonal Allergic Rhinitis and Chronic Asthma

Conditions
-----------------
Rhinitis, Allergic, Seasonal, Asthma, Bronchial

Intervention / Treatment
-----------------
* Drug: MK0476, montelukast sodium
* Drug: Comparator: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-smoker A 2-year documented history of seasonal allergic rhinitis A 1-year documented history of chronic asthma Positive allergy testing Exclusion Criteria: Medical history of a lung disorder (other than asthma) or a recent upper respiratory tract infection.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0476, montelukast sodium|nan|
|Drug: Comparator: placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily Rhinitis Symptoms score; the Daytime Nasal Symptoms score and Nighttime Symptoms score |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| (1) Rhinoconjunctivitis Quality-of-Life Questionnaire overall score; (2) Global Evaluation of Allergic Rhinitis by Patient; (3) Global Evaluation of Allergic Rhinitis by Physician |  |  |
Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)

Study Overview
=================
Brief Summary
-----------------
This study will compare the effectiveness of ondansetron (Zofran) and naltrexone (ReVia) both alone and in combination in treating Early Onset Alcoholics versus Late Onset Alcoholics. All subjects will received standardized Cognitive Behavioral Therapy. Followup assessments will be completed at 1, 3, 6, and 9 months after treatment.

Conditions
-----------------
Alcoholism

Intervention / Treatment
-----------------
* Drug: ondansetron (Zofran)
* Drug: naltrexone (ReVia)
* Behavioral: Cognitive Behavioral Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Current diagnosis of alcohol dependence. Provide a written informed consent. Must weigh within 30% of their ideal body weight. Patients must weigh at least 89 lbs. and no more than 342 lbs. Good physical health. Currently drinking 14 or more alcohol units per week for women and 21 or more alcohol units per week for men in the last 30 days. Provide evidence of stable residence in the last month prior to enrollment in the study. No plans to move in the nine months after entering the study. Literate in English and able to read, understand, and complete questionnaires and follow instructions. Willingness to participate in behavioral treatment for alcoholism. Exclusion Criteria: Current psychiatric disorder other than alcohol or nicotine dependence. Elevated liver enzymes or elevated bilirubin. Severe alcohol withdrawal symptoms which require treatment. Serious medical co-morbidity requiring medical intervention or close supervision. Severe or life-threatening adverse reactions to medications in the past or during this trial. Female patients who are pregnant, lactating, or not adhering to an acceptable form of contraception at any time during the study. Received inpatient or outpatient treatment for alcohol dependence within the last 30 days. Compelled to participate in an alcohol treatment program for alcohol dependence to maintain their liberty. Members of the same household. Tuberculosis. Current treatment with any medications having a potential effect on alcohol consumption and related behaviors or mood. Urine must be free of opiates, cocaine, amphetamines, barbiturates, benzodiazepines, prescription and non-prescription drugs. Pyrexia of unknown origin.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ondansetron (Zofran)|nan|
|Drug: naltrexone (ReVia)|nan|
|Behavioral: Cognitive Behavioral Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Special Drug Use-Results Survey of Lipitor Tablets

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate the controlling effect of atrovastatin on plasma lipid to achieve the category-specific targeted lipid levels.

Detailed Description
-----------------
To confirm the low-density lipoprotein cholesterol (LDL-C)-lowering effect of 24 weeks of treatment with Lipitor®(Generic Name : atorvastatin calcium) Tablets and determine the rate of achievement of the category-specific target LDL-C level in patients with hypercholesterolemia; and to confirm the usefulness (efficacy and safety) of atorvastatin in patients who have not responded sufficiently to other statin therapies

Official Title
-----------------
Special Drug Use-Results Survey of Lipitor Tablets

Conditions
-----------------
Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: atrovastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients with hypercholesterolemia who have not achieved the category-specific target lipid level
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| atrovastatin group<br>Who receive atrovastatin | Drug: atrovastatin<br>* oral<br>* Other names: Lipitor;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in plasma LDL-C concentration |  | 0, 4, 12 and 24 week | 
| Change in rate of achievement of the category-specific target LDL-C level |  | 0, 4, 12 and 24 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in plasma lipid values (LDL cholesterol, HDL cholesterol, triglycerides, total cholesterol, and malondialdehyde-modified LDL [MDL-LDL]) |  | 0, 4, 12 and 24 week | 
| Changes in renal function test values (urinary albumin, urinary creatinine, urinary protein, and serum creatinine) |  | 0, 4, 12 and 24 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lipitor, HMG-CoA reductase inhibitor
Low Fluoroscopy Afib Ablation Registry

Study Overview
=================
Brief Summary
-----------------
Prospective data collection of patients undergoing Atrial Fibrillation Ablation.

Detailed Description
-----------------
Clinicians who have experience using low dose fluoroscopy including use of Carto Mapping system will consent patients to allow data collection and a 12 month f/up visit to track adverse events. Clinicians will follow a protocol which will be similar to their standard of care for ablations.

Official Title
-----------------
A Multi Center Registry of Low- Fluoroscopy Atrial Fibrillation Ablation Using Electroanatomic Mapping Carto

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Procedure: Ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient meets accepted AHA/ACC/HRS guideline indications for catheter ablation of paroxysmal or persistent AF First or subsequent ablation procedures may be included Age 18-75 Exclusion Criteria: Known venous malformations or implanted instrumentation (IVC filter) Known PV stenosis Unable to provide consent H/O mechanical mitral valve replacement (unable to rely on EA mapping only) Documented left atrial thrombus Prior ASD repair Pregnancy NYHA >=3 EF less than 35% CHF within 90 daysRecent MI or coronary revascularization within 90 days NOTE: H/O implanted pacemaker or ICD with transvenous leads will NOT be an exclusion criteria, but we will track patients treated with pre-existing transvenous leads with the hypothesis that although fluoroscopy use will be higher in these patients compared to those without leads, but still lower than conventionally treated patients. Patients who are undergoing non- standard of care ablations ie, Cyro or FIRM ablations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Ablation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Atrial Fibrillation | Determine Atrial Fibrillation burden at 12 month visit by reviewing monitoring systems that capture this data | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fluoroscopic Usage | To determine total amount of radiation used at each procedure by estimation of mGy | post operative |